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Immunotherapy against cancer has shown increased overall survival of metastatic cancer patients 
and is a promising new vaccine target. For this to succeed, appropriate tailoring of vaccine 
formulations to mount in vivo cytotoxic T cell (CTL) responses towards co-delivered cancer 
antigens is important. Previous development of therapeutic cancer vaccines has largely been based 
on studies in mice and the majority of these candidate vaccines failed to establish therapeutic 
responses in subsequent human clinical trials. Since the porcine immunome is more closely related 
to the human counterpart, we here introduce pigs as a superior large animal model for human cancer 
vaccine development via the use of our unique technology for swine leukocyte antigen (SLA) 
production. IDO and RhoC, both known to be important in human cancer development and 
progression, were used as vaccine targets. Pigs were immunized with overlapping 20-mer peptides 
spanning the entire porcine IDO and RhoC sequences formulated in a panel of CTL-inducing 
adjuvants. 198 candidate IDO- and RhoC-derived 9-11mer peptides potentially binding to SLA-
1*04:01, -1*07:02, -2*04:01, -2*05:02 and/or -3*04:01 were identified in silico, and peptide-SLA 
complex stability measurements revealed 89 stable (t½ ≥ 0.5 hour) complexes. Vaccine-induced 
peptide-specific CTL responses were monitored using IFN-γ release as a read out. We found 
responses to IDO- and RhoC-derived peptides across all groups; surprisingly non-stably binding 
peptides also induced responses. None of the adjuvants was found to be superior as they were all 
capable of generating CTL responses to IDO and RhoC hence supporting the further use of pigs as a 
large animal model for vaccine development against human cancer.  
 
